Pemafibrate was tied to potential prevention of leg and foot ulcers in type 2 diabetes, a silver lining to the PROMINENT trial's otherwise disappointing cardiovascular results. In an exploratory ...
In an experimental model of SLD in female rats, pemafibrate prevents the development of hepatic steatosis, increases fatty acid catabolism and cholesterol clearance in the liver, and shows a good ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback